These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22388666)

  • 21. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
    Dall'Era MA; Konety BR
    Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
    Leibovici D; Lindner A; Stay K; Zisman A
    Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Localised prostate cancer - current treatment options.
    Duchesne G
    Aust Fam Physician; 2011 Oct; 40(10):768-71. PubMed ID: 22003477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
    Klotz LH; Nam RK
    Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment options for localized prostate cancer.
    Mohan R; Schellhammer PF
    Am Fam Physician; 2011 Aug; 84(4):413-20. PubMed ID: 21842788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active surveillance for prostate cancer: progress and promise.
    Cooperberg MR; Carroll PR; Klotz L
    J Clin Oncol; 2011 Sep; 29(27):3669-76. PubMed ID: 21825257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
    Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
    J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An economic analysis of conservative management versus active treatment for men with localized prostate cancer.
    Perlroth DJ; Bhattacharya J; Goldman DP; Garber AM
    J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):250-7. PubMed ID: 23271781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cumulative cost pattern comparison of prostate cancer treatments.
    Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
    Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes and follow-up strategies for patients on active surveillance.
    Dall'Era MA; Carroll PR
    Curr Opin Urol; 2009 May; 19(3):258-62. PubMed ID: 19295434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.